Patents Issued in December 17, 2019
-
Patent number: 10507220Abstract: A method of increasing beta-islet cells from pancreases of rabbits and a composition for transplantation of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among diabetic patients.Type: GrantFiled: March 13, 2014Date of Patent: December 17, 2019Assignee: Philadelphia Medical Scientific Center L.L.C.Inventors: Vladislav Broytman, Nikanor Broytman, Nikolay Skaletskiy
-
Patent number: 10507221Abstract: Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.Type: GrantFiled: December 21, 2018Date of Patent: December 17, 2019Assignee: Vedanta Biosciences, Inc.Inventors: Rose L. Szabady, Bernat Olle, Bruce Roberts
-
Patent number: 10507222Abstract: The present invention provides a lactobacillus that improves hyperuricemia, fatty liver and a lifestyle-related disease, and a composition containing the lactobacillus.Type: GrantFiled: May 28, 2015Date of Patent: December 17, 2019Assignee: NITTO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Yasunori Yonejima, Keiko Hisa, Yoshie Uchibori
-
Patent number: 10507223Abstract: A horizontal axis rotary separation apparatus is deployed in a process for separating resinous trichomes rich in flavoring, aromatic and/or medicinal components produced in plant trichome glands from unwanted plant matter. The process physically separates resin rich beads at the trichome gland head from extraneous plant matter by one or move separation sieves. The sieves are provided in or as a casing over a rigid frame member. The sieves are mesh fabric bags or screen that are easily opened and replenished in a batch operating mode, and are removable from the frame for cleaning and maintenance. Other aspects of the invention include processes that improve process efficiency and speed, and yield products of superior quality.Type: GrantFiled: July 4, 2017Date of Patent: December 17, 2019Assignee: The Original Resinator LLCInventors: James Eugene Watts, Travis Jeremy Arnovick
-
Patent number: 10507224Abstract: The present invention relates to a composition for muscle function improvement or exercise ability enhancement, the composition including kirenol, a Siegesbeckia herba extract, or a fraction of the Siegesbeckia herba extract as an active ingredient. Kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an excellent effect of increasing muscle mass by increasing the protein expression of p-mTOR, which is a major gene concerned with muscle functions. Also, kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an effect of remarkably enhancing exercise ability by increasing the protein expression of PGC-1?, which is a major gene concerned with exercise ability. In addition, the present invention is a natural product, and thus is safe for use without side effects and can be used as a medicine or food.Type: GrantFiled: December 27, 2016Date of Patent: December 17, 2019Assignee: AAT Costech Co., Ltd.Inventors: Jae-Kwan Hwang, Mi-Bo Kim, Chang Hee Kim
-
Patent number: 10507225Abstract: The present disclosure relates to the field of health care products. The present disclosure provides a powder which is prepared from xylooligosaccharide, isomaltooligosaccharide, mannitol, inulin, RADIX CODONOPSIS, FRUIT BODY HERICIUM ERINACEUS extract, RHIZOMA DIOSCOREA OPPOSITA, SCLEROTIUM PORIA, SEMEN DOLICHOS, PERICARPIUM CITRUS, FRUCTUS AMOMUM and RHIZOMA MACROCEPHALA. All raw materials are from natural Chinese herbal medicine. No additives are added. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. Experiment data shows that the powder described in the present disclosure has the function of relieving the gastric mucosal injury by reducing the acute gastric mucosal injury induced by ethanol effectively and has the function of regulating gastric mucosa.Type: GrantFiled: April 18, 2018Date of Patent: December 17, 2019Assignee: INFINITUS (CHINA) COMPANY LTD.Inventors: Lei Wang, Ruiqi He, Hongwei Zhao, Qingtao Tang
-
Patent number: 10507226Abstract: Disclosed herein are compounds comprising short N-aminated peptides and compositions comprising the same. The disclosed compounds and compositions maybe used in methods of inhibiting amyloid-beta aggregation and treating Alzheimer's disease.Type: GrantFiled: December 21, 2018Date of Patent: December 17, 2019Assignee: University of South FloridaInventor: Juan R. Del Valle
-
Patent number: 10507227Abstract: A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: Bn1-Z;??(a) Bn1-Z-Bn2; and??(b) Z-Bn1??(c) wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.Type: GrantFiled: April 15, 2015Date of Patent: December 17, 2019Assignee: The Hospital for Sick ChildrenInventor: Charles M. Deber
-
Patent number: 10507228Abstract: Stapled peptides and methods of using them to inhibit the Kras/Raf interaction are disclosed herein.Type: GrantFiled: April 20, 2016Date of Patent: December 17, 2019Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Said M. Sebti, Jianfeng Cai
-
Patent number: 10507229Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: March 27, 2018Date of Patent: December 17, 2019Assignee: Saint Regis Mohawk TribeInventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 10507230Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: GrantFiled: March 28, 2018Date of Patent: December 17, 2019Assignee: TOKUSHIMA UNIVERSITYInventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
-
Patent number: 10507231Abstract: The invention relates to a matrix in ball form comprising cross-linked fibrinogen, the matrix being free from fibrin, as well as to a method for preparing such a matrix, comprising the following steps: (a) providing an initial composition comprising fibrinogen and a platelet factor; (b) injecting said initial composition into an oil heated to a temperature of 50° C. to 80° C. so as to form an emulsion; (c) mixing the emulsion thus obtained at a temperature of 50° C. to 80° C. until a matrix in ball form is obtained; and (d) isolating the matrix thus obtained. The matrix is used as a cell carrier.Type: GrantFiled: February 2, 2016Date of Patent: December 17, 2019Assignee: Maco PharmaInventors: Thomas Bouckenooghe, Pauline Bertholet, Bruno Delorme
-
Patent number: 10507232Abstract: The subject invention pertains to materials and methods for the treatment of latent viral infections.Type: GrantFiled: April 2, 2015Date of Patent: December 17, 2019Assignees: University of Florida Research Foundation, Incorporated, Duke UniversityInventors: David C. Bloom, Dane M. Phelan, Bryan R. Cullen, Matthew E. Kennedy
-
Patent number: 10507233Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: August 20, 2018Date of Patent: December 17, 2019Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Patent number: 10507234Abstract: The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.Type: GrantFiled: July 13, 2016Date of Patent: December 17, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS DIDEROT—PARIS 7Inventors: Roberto Mallone, Slobodan Culina, Nimesh Gupta, Sebastien Lacroix-Desmazes
-
Patent number: 10507235Abstract: One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma. The method includes the step of administering to an individual who has chordoma, an immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. Another embodiment of the invention relates to the use of an immunotherapeutic composition comprising a yeast vehicle and a cancer antigen comprising at least one Brachyury antigen to chordoma in an individual who has chordoma. Yet another embodiment of the invention relates to the use an immunotherapeutic composition comprising a yeast vehicle.Type: GrantFiled: March 19, 2014Date of Patent: December 17, 2019Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Timothy C. Rodell, David Apelian, Claudia Palena, Jeffrey Schlom
-
Patent number: 10507236Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalizing an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.Type: GrantFiled: October 9, 2015Date of Patent: December 17, 2019Assignees: Lipotek Pty Ltd, The Australian National UniversityInventors: Jason David Price, Christopher Parish, Ines Atmosukarto
-
Patent number: 10507237Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.Type: GrantFiled: June 19, 2015Date of Patent: December 17, 2019Assignee: The Pirbright InstituteInventors: Charles Abrams, Ana-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
-
Patent number: 10507238Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.Type: GrantFiled: January 19, 2018Date of Patent: December 17, 2019Assignees: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC., IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
-
Patent number: 10507239Abstract: HIV-1 envelope proteins and fragments that possess naturally occurring and novel engineered epitopes that can be used to elicit (and are recognized by) broadly neutralizing antibodies.Type: GrantFiled: June 27, 2017Date of Patent: December 17, 2019Assignee: The Regents of the University of CaliforniaInventors: Phillip Berman, Gwen Tatsuno, Bin Yu, Javier Morales, Kathryn Mesa
-
Patent number: 10507240Abstract: The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.Type: GrantFiled: November 27, 2015Date of Patent: December 17, 2019Assignee: CELLTRION, Inc.Inventors: Joon Sun Yoon, Hwa Jin Lee, Kye Sook Yi, Cheol Min Kim, Byung Pil Lim, Shin Jae Chang, Seung Suh Hong
-
Patent number: 10507241Abstract: This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.Type: GrantFiled: July 23, 2015Date of Patent: December 17, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Sudha Visvanathan, Patrick Baum, Oliver Kleiner, Ulrich Kunz
-
Patent number: 10507242Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.Type: GrantFiled: January 9, 2017Date of Patent: December 17, 2019Assignee: GENZYME CORPORATIONInventors: Jay Harper, Scott Lonning, Frank Hsu
-
Patent number: 10507243Abstract: Described are stable nanoparticle complexes comprising paclitaxel, albumin and rituximab. The nanoparticle complexes are suitable for the treatment of cancer.Type: GrantFiled: January 24, 2017Date of Patent: December 17, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 10507244Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: GrantFiled: June 19, 2017Date of Patent: December 17, 2019Assignee: Potenza Therapeutics, Inc.Inventors: Daniel Hicklin, William Winston, Cynthia Seidel-Dugan, Nels P. Nielson
-
Patent number: 10507245Abstract: An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more ?1 adrenergic agonists or antagonists is disclosed. The ophthalmic formulation may enable treatment of conditions adversely affecting the visual acuity of a patient, including presbyopia. A method of using the disclosed ophthalmic formulation to treat or ameliorate symptoms of presbyopia is also disclosed.Type: GrantFiled: July 19, 2012Date of Patent: December 17, 2019Inventor: Luis Felipe Vejarano Restrepo
-
Patent number: 10507246Abstract: This invention discloses a method for preparing TDNs-AS1411-nucleic acid drug nanocomposite based drug delivery system, which includes the following steps: binding AS1411 and nucleic acid drug to a tetrahedral DNA nanostructure respectively; selecting four DNA single strands that respectively carry AS1411 and nucleic acid drug; mixing the four DNA single strands; mixing the DNA single strands and the TM buffer uniformly; putting the mixture into a PCR apparatus; raising the temperature to 95° C. quickly and maintaining for 10 min; and next cooling down to 4° C. and maintaining for 20 min to obtain the TDNs-AS1411-nucleic acid drug nanocomposite based drug delivery system. This drug delivery system can directly act on cell nucleus and will not be degraded by lysosomal. The targeting specificity is good. The drug can take a good efficacy and the pertinency is high.Type: GrantFiled: November 21, 2016Date of Patent: December 17, 2019Assignee: Sichuan UniversityInventors: Yunfeng Lin, Sirong Shi, Xiaoxiao Cai, Shiyu Lin, Qianshun LI
-
Patent number: 10507247Abstract: An optical probe is presented comprising at least one fluorophore connected to at least one quencher by an enzyme cleavable peptide sequence; the or each fluorophore being substantially fluorescently quenched by the at least one quencher when connected to the enzyme cleavable peptide sequence; the or each fluorophore is separated from the at least one quencher when the enzyme cleavable peptide sequence of the at least one probe element is cleaved; and the enzyme cleavable peptide sequence is selectively cleavable by one or more matrix metalloproteinase (MMP). Methods of use of the optical probe are also presented.Type: GrantFiled: March 18, 2016Date of Patent: December 17, 2019Assignee: The University of the University of EdinburghInventors: Mark Bradley, Sunay Vijaykumar Chankeshwara, Alicia Megia-Fernandez
-
Patent number: 10507248Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.Type: GrantFiled: August 9, 2017Date of Patent: December 17, 2019Assignee: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Patent number: 10507249Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: July 3, 2019Date of Patent: December 17, 2019Assignee: Translate Bio, Inc.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 10507250Abstract: Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.Type: GrantFiled: September 8, 2017Date of Patent: December 17, 2019Assignee: Institute of Nuclear Energy Research, Atomic Energy Council, Executive YuanInventors: Ming-Hsin Li, Chyng-Yann Shiue, Han-Chih Chang, Chun-Fang Feng
-
Patent number: 10507251Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: GrantFiled: May 17, 2019Date of Patent: December 17, 2019Assignee: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Patent number: 10507252Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.Type: GrantFiled: March 16, 2017Date of Patent: December 17, 2019Inventor: Paul C. Lee
-
Patent number: 10507253Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.Type: GrantFiled: August 17, 2017Date of Patent: December 17, 2019Inventor: Paul C. Lee
-
Patent number: 10507254Abstract: A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.Type: GrantFiled: March 25, 2019Date of Patent: December 17, 2019Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research CenterInventor: Mamdooh Alqathami
-
Patent number: 10507255Abstract: A remote control having an ultraviolet light emitting device for disinfecting the outer surfaces of the remote control is disclosed. In particular, the remote control may include an ultraviolet transmissive housing and internal ultraviolet emitting light emitting diodes. The ultraviolet transmissive housing allows the light from the internally mounted ultraviolet emitters to pass through the remote control's housing and kill bacteria, viruses, and other micro-organisms on the outer surface of the remote control by employing methods to automate safe and effective operations of ultraviolet light.Type: GrantFiled: May 31, 2017Date of Patent: December 17, 2019Assignee: DISH TECHNOLOGIES L.L.C.Inventors: Phuc H. Nguyen, Christopher William Bruhn
-
Patent number: 10507256Abstract: Provided are mobile decontamination units and methods of using such units for decontaminating various areas, such as aircraft cabins. A mobile decontamination unit comprises at least one aerosol dispersing nozzle and at least one aerosol directing fan. The nozzle disperses disinfectant in the aerosol form, while the fan directed this aerosol to surfaces being decontaminated. Aerosol dispersing parameters, such the nozzle and fan orientations, dispersing rate, fan speed, and the like, are determined based on area characteristics. Specifically, orientations of different surfaces, temperature, humidity and/or other like characteristics may be considered. Some characteristics may be obtained by the mobile decontamination unit after its deployment in the area, such as using its sensors. Other characteristics, such as area layout, may be preloaded to the mobile decontamination unit prior to its deployment. The dispersing parameters are determined to ensure through decontamination of the surfaces in the area.Type: GrantFiled: January 27, 2017Date of Patent: December 17, 2019Assignee: The Boeing CompanyInventors: Shawn Hyunsoo Park, Leora Peltz, Andrew Gerhard Wallburg
-
Patent number: 10507257Abstract: A gel composition for air freshening or disinfecting, comprising a silicon alkoxide or colloidal silica, a volatile or gaseous fragrance and/or disinfectant, water, an acid or base catalyst, a water-soluble solvent, and optionally other volatile components and additives, and a method for preparing the same. The gel can be transparent or colored, has a homogeneous texture and a soft to rigid structure, and contains volatile or gaseous components from 0 vol % to 85 vol % for scented materials (fragrance and oils) and/or 0-8000 ppm of disinfectant, which are released at a steady rate under ambient conditions, controlled by the shape and opening of the gel container. Botanicals or plastic decorations may be added into the gel to improve its aesthetic appeal. The preparation method is easier and requires less energy consumption and the gel is used as an air freshener or disinfectant.Type: GrantFiled: October 30, 2018Date of Patent: December 17, 2019Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: King Lun Yeung, Wei Han, Shengli Cao, Wai Kwong Ching
-
Patent number: 10507258Abstract: A new diffuser for essential oils and the like is rendered more compact by integrating the entire diffuser into a form of cap threaded to fit a bottle operating as a reservoir. The motor and pump system are integrated into a package sleeved inside a housing that then receives in a silo beside the pump and motor the entire reservoir and diffuser system. Simplified control algorithms provide a limited set of buttons that are more intuitive by which a user need only define total time of operation, some level of intensity of scent, and an indication of the comparative size of the space to be conditioned by the diffused scent.Type: GrantFiled: January 9, 2017Date of Patent: December 17, 2019Inventor: Earl Vaughn Sevy
-
Patent number: 10507259Abstract: A flexible absorbent pad has a dry thickness of between 2 mm and 10 mm and a difference in flexural-resistance between the dry state and the wet state of an absorbent center zone of the absorbent pad of less than 100 grams-force. The absorbent core of the pad may include an airlaid, a foam, or a fibrous staple filament. The absorbent core of the absorbent pad may be corrugated, such as with flexure hinges, in which case adhesive is applied to the backsheet of the absorbent pad in a pattern that leaves the flexure hinges devoid of adhesive so that the backsheet is attached to the absorbent core in a manner that does not impede the flexing of the flexure hinges.Type: GrantFiled: May 9, 2016Date of Patent: December 17, 2019Assignee: FIRST QUALITY RETAIL SERVICES, LLCInventors: James William Cree, Jocelyn Rice
-
Patent number: 10507260Abstract: The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides an absorbent foam, suitable for packing antrums or other cavities of the human or animal body, comprising a biodegradable synthetic polymer, which polymer preferably comprises —C(O)—O— groups in the backbone of the polymer, for instance polyurethane and/or polyester units combined with polyethers.Type: GrantFiled: April 24, 2015Date of Patent: December 17, 2019Assignee: Stryker European Holdings I, LLCInventors: Catharina Everdina Hissink, Theodorus Adrianus Cornelius Flipsen, Johan Zuidema, Linda Joan Gibcus
-
Patent number: 10507261Abstract: A pasty two-component polymethacrylate bone cement comprising a pasty component A, containing AI at least one distillable methacrylate monomer for radical polymerisation; AII at least one polymer soluble in AI; AIII at least one particulate polymer with a particle size of no more than 500 ?m that is not soluble in AI; AIV at least one radical stabiliser; and AV at least one aromatic amine accelerator; and a pasty component B, containing BI dibenzoyl peroxide; BII at least one substance that is not subject to radical polymerisation and is liquid at room temperature, whereby the solubility of dibenzoyl peroxide in this substance at room temperature is less than 5.0% by weight and, whereby the weight fraction of liquid substance BII in the self-curing cement dough is less than 2.0% by weight. Also disclosed is a method for producing a self-curing bone cement dough using the pasty two-component polymethacrylate bone cement.Type: GrantFiled: June 6, 2017Date of Patent: December 17, 2019Assignee: HERAEUS MEDICAL GMBHInventors: Sebastian Vogt, Thomas Kluge
-
Patent number: 10507262Abstract: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.Type: GrantFiled: March 23, 2017Date of Patent: December 17, 2019Assignee: C.P. MEDICAL CORPORATIONInventors: Syed H. Askari, Yeon S. Choi
-
Patent number: 10507263Abstract: Borate-glass biomaterials comprising: aNa2O. bCaO. cP2O5. dB2O3 wherein a is from about 1-40 wt %, b is from about 10-40 wt %, c is from about 1-40 wt %, and d is from about 35-80 wt %; and wherein the biomaterial has a surface area per mass of more than about 5 m2/g. Methods of making and uses of these biomaterials.Type: GrantFiled: June 9, 2015Date of Patent: December 17, 2019Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Showan Nazhat, William Cole Lepry
-
Patent number: 10507264Abstract: The present disclosure relates to hydrogels and their use for repairing or supplementing body tissue. The hydrogels are capable of safe injection into patients through fine gauge needles and are suitable for repairing or supplementing the nucleus pulposus of an intervertebral disc. Methods of manufacturing and methods of using the hydrogels of the present disclosure to repair or replace tissues are also disclosed.Type: GrantFiled: January 7, 2019Date of Patent: December 17, 2019Assignee: REGELTEC, INC.Inventors: Anthony Lowman, Erik Brewer, Nigel Gordon Smith
-
Patent number: 10507265Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation.Type: GrantFiled: May 16, 2017Date of Patent: December 17, 2019Assignee: NuVasive, Inc.Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy
-
Patent number: 10507266Abstract: A method according to the present invention for producing a cartilage-damage treatment agent, includes the steps of: (i) proliferating mesenchymal stem cells in a serum-free medium A containing an FGF, a PDGF, a TGF-?, an HGF, an EGF, at least one phospholipid and at least one fatty acid; and (ii) mixing the mesenchymal stem cells thus proliferated in the step (i), an isotonic preserving agent, and a cytoprotective agent. This method provides a cartilage-damage treatment agent which favorably regenerates a cartilage tissue.Type: GrantFiled: August 1, 2014Date of Patent: December 17, 2019Assignee: TWO CELLS Co., Ltd.Inventors: Koichiro Tsuji, Minoru Morikawa, Satoshi Maeda, Yui Kitayama, Aki Ohmori, Jin Chang Shao, Shinichi Hasegawa, Yukio Kato, Takashi Matsushita, Masato Takao, Shinya Miki, Ken Innami, Yasufumi Takahashi
-
Patent number: 10507267Abstract: Antibacterial coatings and methods of making the antibacterial coatings are described herein. In particular, a method for forming an organocatalyzed polythioether coating is provided in which a first solution including a bis-silylated dithiol and a fluoroarene is prepared. A second solution including an organocatalyst is prepared. The first solution and the second solution are mixed to form a mixed solution. The mixed solution is applied to a substrate, and the substrate is cured.Type: GrantFiled: April 25, 2017Date of Patent: December 17, 2019Assignees: INTERNATIONAL BUSINESS MACHINES CORPORATION, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Amos Cahan, Mareva B. Fevre, James L. Hedrick, Nathaniel H. Park, Theodore G. van Kessel, Rudy J. Wojtecki, Yi Yan Yang
-
Patent number: 10507268Abstract: A medical appliance or prosthesis may comprise one or more layers of electrospun nanofibers, including electrospun polymers. The electrospun material may comprise layers including layers of polytetrafluoroethylene (PTFE). Electrospun nanofiber mats of certain porosities may permit tissue ingrowth into or attachment to the prosthesis.Type: GrantFiled: March 14, 2013Date of Patent: December 17, 2019Assignee: MERIT MEDICAL SYSTEMS, INC.Inventors: John William Hall, Bart Dolmatch, Zeke Eller, Robert S. Kellar, Rachel Lynn Simmons, Wayne L. Mower
-
Patent number: 10507269Abstract: A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial.Type: GrantFiled: April 3, 2019Date of Patent: December 17, 2019Assignee: Medline Industries, Inc.Inventors: Lecon Woo, William Anderson